| Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome. | |
| | |
MedLine Citation:
|
PMID: 16533192 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: We conducted a pilot trial to assess the effect of botulinum toxin B on palmar pain and discomfort in carpal tunnel syndrome (CTS) patients. Design. Randomized, double-blind, placebo-controlled. PATIENTS: Twenty ambulatory CTS patients. Intervention. Botulinum toxin B or placebo injections into three hypothenar muscles anatomically linked or attached to the carpal tunnel and its tentorium, that is, the Opponens Digiti Minimi and Flexor Digiti Minimi, located with electromyography (EMG), and the Palmaris Brevis Muscle, anatomically located without EMG. SETTING: New York City hospital. OUTCOME MEASURES: Outcomes were measured with numeric ratings, with higher scores indicating worse outcomes. Daily, subjects recorded their 0-10 numeric ratings of overall pain levels and pain-related sleep disturbances. During weekly telephone calls, they reported their 0-10 ratings for overall pain, pain-related sleep disturbance, and CTS-related tingling during the night and day as experienced over the preceding 24 hours. For each of four clinic visits, we averaged each subject's ratings of nine quality of life indicators from the West Haven-Yale Multidimensional Pain Inventory (WHYMPI), each measured on a 0-6 numeric scale. RESULTS: Over the 13-week trial, compared to baseline scores, the following outcomes predominantly showed decreases of statistical significance (P < or = 0.050) or borderline significance (0.050 < P < or = 0.10) for weeks 2 through 8: overall pain per daily diary entries and per weekly telephone reports, and pain-related sleep disturbance in the placebo group per phone report and in the botulinum toxin B group per diary report. CTS painful night tingling and day tingling, as well as the average scores of the WHYMPI quality of life indicators, showed improvements with statistical or borderline significance for almost each follow-up week. Between-group analyses, however, demonstrated that at each follow-up week, there was no statistically significant difference between the two study groups regarding changes from baseline in any study outcome. CONCLUSION: Botulinum toxin B is not dramatically superior to placebo for the relief of CTS symptoms. Possible explanations of the improvements in each study group are explored. |
| | |
Authors:
|
Brenda Breuer; Kevin Sperber; Sylvan Wallenstein; Kiril Kiprovski; Angela Calapa; Barry Snow; Marco Pappagallo |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Pain medicine (Malden, Mass.) Volume: 7 ISSN: 1526-2375 ISO Abbreviation: Pain Med Publication Date: 2006 Jan-Feb |
Date Detail:
|
Created Date: 2006-03-14 Completed Date: 2006-06-01 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100894201 Medline TA: Pain Med Country: United States |
Other Details:
|
Languages: eng Pagination: 16-24 Citation Subset: IM |
Affiliation:
|
Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York 10003, USA. bbruer@chpnet.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Analgesics
/
therapeutic use Botulinum Toxins / therapeutic use* Carpal Tunnel Syndrome / drug therapy*, physiopathology, psychology* Double-Blind Method Dyssomnias / etiology, physiopathology, psychology Electromyography Hand / innervation, physiopathology* Humans Injections, Intramuscular Interviews as Topic Pain / drug therapy*, physiopathology, psychology* Pain Measurement Placebo Effect Placebos / pharmacology Treatment Failure |
| Chemical | |
Reg. No./Substance:
|
0/Analgesics; 0/Botulinum Toxins; 0/Placebos; 0/botulinum toxin type B |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intrathecal hydromorphone for intractable nonmalignant pain: a retrospective study.
Next Document: Experience with the synthetic cannabinoid nabilone in chronic noncancer pain.